Top Ten most popular articles on Pharmafile.com this week!
pharmafile | November 2, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10
Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic mushroom ingredient psilocybin breakthrough therapy designation as a treatment for depression, while GSK announced the results of a three year trial looking into a long lasting injection able to stave off HIV.
However this week’s most popular story was the announcement that the Metropolitan Police are charging ITH Pharma for its role in the deaths of several babies in UK hospitals.
Check out this week’s ten most popular stories on Pharmafile.com!
10. Sanofi teams up with Denali in $1.125bn neurological and inflammatory development deal
Sanofi has sealed the deal with Denali Therapeutics to leverage the latter’s small molecule candidates in the development of new therapies to tackle a variety of neurological and systemic inflammatory diseases, forging a partnership which could prove to be worth in excess of $1.125 billion.
9. AstraZeneca flogs two drug licenses in $922 million deal
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional rights to two of the pharma giant’s drugs.
8. NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health and Care Excellence (NICE) has announced its decision not to recommend Abbvie’s Venclyxto (venetoclax) in combination with Genentech’s Rituxan.
7. President Trump unveils new plans to bring US drug prices in line with the rest of the world
Two weeks before the all-important midterm elections in the US, and after repeated strongly-worded promises, President Trump has unveiled an initiative to finally bring down prescription drug prices in the country.
6. Magic mushroom ingredient psilocybin gains breakthrough therapy designation
The US Food and Drug Administration (FDA) has given psilocybin – the psychoactive ingredient in ‘magic mushrooms’ – breakthrough therapy designation, due to the potential it holds as a treatment for depression.
5. GSK announces results of three year trial into long-lasting HIV injection
GlaxoSmithKline have announced the results of a three year investigation into a long acting, injectable, two-drug HIV regimen at the HIV Glasgow Drug Therapy meeting in Scotland.
4. J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of major adverse cardiovascular (CV) events, making it the “first and only oral diabetes treatment approved with this indication”, according to the manufacturer.
3. Novartis cuts 20% of research projects
Swiss multinational Novartis has cut a fifth of its research projects, as it abandons 90 of its 430 drug development programmes, according to Jay Bradner, president of the Novartis Institutes for Biomedical Research.
2. Not so crystal clear: The EU’s clinical reporting problem
With shocking new findings revealing that around half of all clinical trial results in Europe go unreported, Matt Fellows explores the roots of this not-so-surprising revelation, what can be done, and why it all is so important.
1. Metropolitan Police charge ITH Pharma over IV feed-linked baby deaths
An investigation into the deaths and illnesses of several babies at a number of UK hospitals has prompted London’s Metropolitan Police to levy charges against ITH Pharma for its alleged role in the fatalities.
Related Content
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …
GSK pledges £45m to Fleming Initiative to fight AMR
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …
